Moors, Ellen (2013): Duurzaam Innoveren: de kunst van het verbinden. Oratie Duurzaam Innoveren. Universiteit Utrecht

Publications

2024

Scholarly publications

Kleinhout-Vliek, T. H., Boon, W. P. C., Hagendijk, R. P., Hoekman, J., & Moors, E. H. M. (2024). Together for the greater goods: legitimising social innovation in the pharmaceutical field. Innovation: The European Journal of Social Science Research, 1-25. Advance online publication. https://doi.org/10.1080/13511610.2024.2305908

2023

Scholarly publications

van Beest, W., Boon, W. P. C., Andriessen, D., Zielhuis, M., van der Veen, G., & Moors, E. H. M. (2023). How to involve potential users in eHealth innovation: seven strategies from healthcare and design. Design for Health, 7(3), 307-325. https://doi.org/10.1080/24735132.2023.2266163
Cao, V. A. T., Nguyen, T. Q., Le Quyen, D., Boon, W. P. C., Moors, E. H. M., Dondorp, A. M., de Haan, F., & Amaratunga, C. (2023). Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam. Malaria Journal, 22(1), 1-8. Article 326. https://doi.org/10.1186/s12936-023-04763-4
Guissou, R. M., Amaratunga, C., de Haan, F., Tou, F., Cheah, P. Y., Yerbanga, R. S., Moors, E. H. M., Dhorda, M., Tindana, P., Boon, W. P. C., Dondorp, A. M., & Ouédraogo, J. B. (2023). The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal, 22(1), Article 269. https://doi.org/10.1186/s12936-023-04705-0
https://dspace.library.uu.nl/bitstream/handle/1874/431557/s12936-023-04705-0.pdf?sequence=1
de Haan, F., Amaratunga, C., Thi, V. A. C., Orng, L. H., Vonglokham, M., Quang, T. N., Lek, D., Boon, W. P. C., Dondorp, A. M., & Moors, E. H. M. (2023). Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion. Malaria Journal, 22(1), 1-11. Article 261. https://doi.org/10.1186/s12936-023-04666-4
Hehakaya, C., & Moors, E. H. M. (2023). Institutionalisation of convergent medical innovation: an empirical study of the MRI-guided linear accelerator in the Netherlands and the United States. Innovation: Management, Policy and Practice, 1-22. Advance online publication. https://doi.org/10.1080/14479338.2023.2213212
van den Boom, L. A. T. P., van den Broek, K. L., Kroese, F. M., Moors, E. H. M., & de Ridder, D. (2023). Mental models of the protein shift: Exploring consumers' perceptions of the transition. Appetite, 187, Article 106595. https://doi.org/10.1016/j.appet.2023.106595
Ferreira, G. S., Dijkstra, F. M., Veening-Griffioen, D. H., Boon, W. P. C., Schellekens, H., Moors, E. H. M., van Meer, P. J. K., Stuurman, F. E., & van Gerven, J. M. A. (2023). Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs. Translational Psychiatry, 13(1), Article 74. https://doi.org/10.1038/s41398-023-02353-1
van Oers, L., Feola, G., Runhaar, H., & Moors, E. (2023). Unlearning in sustainability transitions: Insight from two Dutch community-supported agriculture farms. Environmental Innovation and Societal Transitions, 46, 1-16. Article 100693. https://doi.org/10.1016/j.eist.2023.100693
Lukkien, D. R. M., Nap, H. H., Buimer, H. P., Peine, A., Boon, W. P. C., Ket, J. C. F., Minkman, M. M. N., & Moors, E. H. M. (2023). Toward Responsible Artificial Intelligence in Long-Term Care: A Scoping Review on Practical Approaches. The Gerontologist, 63(1), 155-168. Article gnab180. https://doi.org/10.1093/geront/gnab180
Van Hees, S., Greubel, C., Moors, E., & Peine, A. (2023). Valuation in health and ageing innovation practices. Ageing and society, 43(9), 2022 - 2040. Article PII S0144686X21001483. https://doi.org/10.1017/S0144686X21001483

2022

Scholarly publications

van Oers, L., Feola, G., Moors, E., & Runhaar, H. (2022). The politics of deliberate destabilisation in sustainability transitions. Abstract from RGS-IBG Annual International Conference 2022, Newcastle.
Kleinhout - Vliek, T., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2022). Causing headwinds? How Dutch actors conceive situated futures for magistral preparation of pharmaceuticals. Abstract from EASST 2022 (European Association for the Study of Science and Technology) , Madrid, Spain.
de Ridder, D. T. D., van den Boom, L. A. T. P., Kroese, F. M., Moors, E. H. M., & van den Broek, K. L. (2022). How do people understand the spread of COVID-19 infections? Mapping mental models of factors contributing to the pandemic. Psychology & health, 1-20. Advance online publication. https://doi.org/10.1080/08870446.2022.2129054
Douglas, C. M. W., Aith, F., Boon, W., de Neiva Borba, M., Doganova, L., Grunebaum, S., Hagendijk, R., Lynd, L., Mallard, A., Mohamed, F. A., Moors, E., Oliveira, C. C., Paterson, F., Scanga, V., Soares, J., Raberharisoa, V., & Kleinhout-Vliek, T. (2022). Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases. Orphanet Journal of Rare Diseases, 17(1), 1-13. Article 344. https://doi.org/10.1186/s13023-022-02476-6
Mayer, J., Maier, B., Moors, E., & Pruijn, M. (2022). Final Report - Disposable medical products used in the OR at the University Medical Center Utrecht: Defining barriers and circular strategies. Eindhoven University of Technology, Wageningen University of Research, Utrecht Universtiy, UMC Utrecht.
https://dspace.library.uu.nl/bitstream/handle/1874/421049/Mayer_et_al_2022_Final_Report_Research_Disposable_medical_products_used_at_UMCU.pdf?sequence=1
Douglas, C., Aith, F., Cordovil-Oliveira, C., Boon, W., Doganova, L., Hagendijk, R., Hoekman, J., Kleinhout - Vliek, T., Moors, E., Mallard, A., Paterson, F., Grunebaum, S., & Rabeharisoa, V. (2022). Social pharmaceutical innovation: Towards a interdisciplinary research agenda for drugs for rare diseases. Abstract from EU-SPRI Conference 2022, Utrecht, Netherlands.
Kleinhout - Vliek, T., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2022). Legitimising Dutch Social Pharmaceutical Innovation. Abstract from EU-SPRI Conference 2022, Utrecht, Netherlands.
Hollants, B., Chappin, M., Janssen, M., & Moors, E. (2022). Dual use innovation: a systematic literature review and research agenda. Abstract from EU-SPRI Conference 2022, Utrecht, Netherlands.
Hehakaya, C., Sharma, A. M., van der Voort Van Zijp, J. R. N., Grobbee, D. E., Verkooijen, H. M., Izaguirre, E. W., & Moors, E. H. M. (2022). Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States. Advances in Radiation Oncology, 7(5), 1-12. Article 100953. https://doi.org/10.1016/j.adro.2022.100953
Fischer, P. K., Hekkert, M. P., Hüsing, B., & Moors, E. H. M. (2022). Individual versus collective strategies in system building - The case of point-of-care diagnostics in Germany. Technological Forecasting and Social Change, 177, 1-11. Article 121474. https://doi.org/10.1016/j.techfore.2022.121474
van Beest, W., Boon, W. P. C., Andriessen, D., Pol, H., van der Veen, G., & Moors, E. H. M. (2022). A Research Pathway Model for evaluating the implementation of practice-based research: The case of self-management health innovations. Research Evaluation, 31(1), 24-48. https://doi.org/10.1093/reseval/rvab023
van Beest, W., Boon, W. P. C., Andriessen, D., Moors, E. H. M., van der Veen, G., & Pol, H. (2022). Successful implementation of self-management health innovations. Journal of Public Health , 30(3), 721-735. https://doi.org/10.1007/s10389-020-01330-y

2021

Scholarly publications

Kleinhout - Vliek, T., Arentshorst, M., Kalkman, S., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. (2021). Causing headwinds? How Dutch actors conceive situational futures for magistral preparation of pharmaceuticals. Paper presented at Society for Social Studies of Science (4S) 2021 Annual meeting, "Virtual Toronto".
van Oers, L., Feola, G., Runhaar, H., & Moors, E. (2021). Sustainability transitions as processes of unlearning. Abstract from 12th International Sustainability Transitions Conference (IST) 2021 (Online), Karlsruhe.
de Haan, F., Bolarinwa, O. A., Guissou, R., Tou, F., Tindana, P., Boon, W. P. C., Moors, E. H. M., Cheah, P. Y., Dhorda, M., Dondorp, A. M., Ouedraogo, J. B., Mokuolu, O. A., & Amaratunga, C. (2021). To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? PLoS One, 16(8), 1-17. Article e0256567. https://doi.org/10.1371/journal.pone.0256567
Greubel, C., Moors, E. H. M., & Peine, A. (2021). From Mattering to Mattering More: ‘Goods’ and ‘Bads’ in Ageing and Innovation Policy Discourses. International Journal of Environmental Research and Public Health, 18(14), Article 7596. https://doi.org/10.3390/ijerph18147596
van Oers, L., Feola, G., Moors, E., & Runhaar, H. (2021). The politics of deliberate destabilisation for sustainability transitions. Environmental Innovation and Societal Transitions, 40, 159-171. https://doi.org/10.1016/j.eist.2021.06.003
de Haan, F., Moors, E. H. M., Dondorp, A. M., & Boon, W. P. C. (2021). Market Formation in a Global Health Transition. Environmental Innovation and Societal Transitions, 40, 40-59. https://doi.org/10.1016/j.eist.2021.05.003
Tindana, P., de Haan, F., Mokuolu, OA., Guissou, R., Bolarinwa, OA., Ouedraogo, JB., Tou, F., Boon, WPC., Moors, EHM., Dondorp, AM., Dhorda, M., Amaratunga, C., & Cheah, PY. (2021). Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol. Wellcome Open Research, 6(75). https://doi.org/10.12688/wellcomeopenres.16065.1
Hehakaya, C., Moors, E. H. M., Verkooijen, H. M., Grobbee, D. E., Verburg, F. A., & Lam, M. G. E. H. (2021). 177Lu-PSMA for advanced prostate cancer: are we ready to play big? European Journal of Nuclear Medicine and Molecular Imaging, 48, 2325-2328. https://doi.org/10.1007/s00259-020-05102-4
Veening-Griffioen, D. H., Ferreira, G. S., Boon, W. P. C., Gispen-de Wied, C. C., Schellekens, H., Moors, E. H. M., & Van Meer, P. J. K. (2021). Tradition, not science, is the basis of animal model selection in translational and applied research. Altex, 38(1), 49-62. https://doi.org/10.14573/altex.2003301

Professional publications

Boon, W., Verkade, N., Hoekman, J., van der Voort, T., & Moors, E. (2021). Innovation pathways to achieve the moonshot for proof-of-concept therapy for type 1 diabetes. (deliverable 5.3 ‘adapted ELSA’ ed.) RegMed XB .

2020

Scholarly publications

Schilder, I. PA., Veening-Griffioen, D. H., Ferreira, G. S., Meer, P. JK. V., Wied, C. C. G., Schellekens, H., Boon, W. PC., & Moors, E. HM. (2020). Pathways in the Drug Development for Alzheimer's Disease (1906-2016): A Bibliometric Study. Journal of Scientometric Research, 9(3), 277-292. https://doi.org/10.5530/jscires.9.3.35
Dekker, S. C., Kraneveld, A. D., van Dijk, J., Kalfagianni, A., Knulst, A. C., Lelieveldt, H., Moors, E. H. M., Müller, E., Pieters, R. H. H., Pieterse, C. M. J., Rosenkranz, S., Voesenek, L. A. C. J., & van Westen, A. C. M. (2020). Towards Healthy Planet Diets: A Transdisciplinary Approach to Food Sustainability Challenges. Global Challenges, 11(2), Article 21. https://doi.org/10.3390/challe11020021
Hehakaya, C., Van der Voort van Zyp, J. R., Lagendijk, J. J. W., Grobbee, D. E., Verkooijen, H. M., & Moors, E. H. M. (2020). Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer. Frontiers in Oncology, 10, Article 1741. https://doi.org/10.3389/fonc.2020.01741
Boenink, M., van Lente, H., Moors, E. H. M., Oudshoorn, N., Gardner, J., Balka, E., Green, E., Henwood, F., Lynch, R., & Farrington, C. (2020). Innovation. In A. Webster, & S. Wyatt (Eds.), Health, Technology and Society: Critical Inquiries (1 ed., pp. 15-75). Palgrave Macmillan Ltd..
Adenle, A. A., Chertow, M. R., Moors, E. H. M., & Pannell, D. J. (2020). Conclusions and Future Policies for Meeting the Sustainable Development Goals. In A. A. Adenle, M. R. Chertow, E. H. M. Moors, & D. J. Pannell (Eds.), Science, Technology and Innovation for Sustainable Development Goals: Insights from Agriculture, Health, Environment and Energy (pp. 547-558). Oxford University Press. https://doi.org/10.1093/oso/9780190949501.003.0026
Moors, E. H. M., & de Haan, F. (2020). Anti-Malarial Drug Development and Diffusion in an Era of Multidrug Resistance: How Can an Integrated Health Framework Contribute to Sustainable Development Goal 3? . In A. A. Adenle, M. R. Chertow, E. H. M. Moors, & D. J. Pannell (Eds.), Science, Technology and Innovation for Sustainable Development Goals: Insights from Agriculture, Health, Environment and Energy (pp. 265-287). Oxford University Press. https://doi.org/10.1093/oso/9780190949501.003.0013
Adenle, A. A., Chertow, M. R., Moors, E. H. M., & Pannell, D. J. (2020). What Can Science, Technology, and Innovation Offer in the Achievement of Sustainable Development Goals? In A. A. Adenle, M. R. Chertow, E. H. M. Moors, & D. J. Pannell (Eds.), Science, Technology and Innovation for Sustainable Development Goals: Insights from Agriculture, Health, Environment and Energy (pp. 3-19). Oxford University Press. https://doi.org/10.1093/oso/9780190949501.003.0001
Adenle, A. A., Chertow, M. R., Moors, E. H. M., & Pannell, D. J. (2020). Science, Technology and Innovation for Sustainable Development Goals: Insights from Agriculture, Health, Environment and Energy. Oxford University Press. https://doi.org/10.1093/oso/9780190949501.001.0001
van Oers, L. M., Feola, G., Moors, E. H. M., & Runhaar, H. A. C. (2020). Exnovation for sustainability transitions: broadening an emerging research field with insights from political economy. Abstract from The 11th International Sustainability Transition conference (IST).
Ferreira, G. S., Veening-Griffioen, D. H., Boon, W. P. C., Moors, E. H. M., & van Meer, P. J. K. (2020). Levelling the Translational Gap for Animal to Human Efficacy Data. Animals, 10(7), Article 1199. https://doi.org/10.3390/ani10071199
Runhaar, H., Fünfschilling, L., van den Pol-Van Dasselaar, A., Moors, E. H. M., Temmink, R., & Hekkert, M. (2020). Endogenous regime change: Lessons from transition pathways in Dutch dairy farming. Environmental Innovation and Societal Transitions, 36, 137-150. https://doi.org/10.1016/j.eist.2020.06.001
Strohm, L., Hehakaya, C., Ranschaert, E. R., Boon, W. P. C., & Moors, E. H. M. (2020). Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors. European Radiology, 30, 5525-5532. https://doi.org/10.1007/s00330-020-06946-y
Ferreira, G. S., Veening-Griffioen, D. H., Boon, W. P. C., Hooijmans, C. R., Moors, E. H. M., Schellekens, H., & van Meer, P. J. K. (2020). Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis. European Journal of Pharmacology, 879, Article 173153. https://doi.org/10.1016/j.ejphar.2020.173153
Kalkman, S., Arentshorst, M., Hoekman, J., Boon, W., Uijtendaal, E., van Thiel, G., & Moors, E. (2020). In-Hospital Production of Medicines: Preparing for Disruption. Trends in Biotechnology, 38(10), 1045-1047. https://doi.org/10.1016/j.tibtech.2019.09.011
van Weele, M. A., van Rijnsoever, F. J., Groen, M., & Moors, E. H. M. (2020). Gimme shelter? Heterogeneous preferences for tangible and intangible resources when choosing an incubator. The Journal of Technology Transfer, 45, 984-1015. https://doi.org/10.1007/s10961-019-09724-1

Professional publications

Rosenthal, U., Benschop, J. P. H., Cools, R., Debackere, K., van der Hagen, T. H. J. J., Heimovaara, S., Moors, E. H. M., Mousaoui, C., Stikker, M., & Essers, P. W. J. (2020). Advies: Beter van start - De sleutel tot doorgroei van kennisintensieve start-ups. Adviesraad voor wetenschap, technologie en innovatie (AWTI). https://www.awti.nl/documenten/adviezen/2020/10/07/advies-beter-van-start---de-sleutel-tot-doorgroei-van-kennisintensieve-start-ups

2019

Scholarly publications

Amaratunga, C., Dhorda, M., Van Der Pluijm, R., Tarning, J., Aguas, R., Boni, M. F., Cheah, P. Y., Tindana, P., De Haan, F., Boon, W., Moors, E. H., Plewes, K., Tripura, R., Day, N. P., White, N. J., & Dondorp, A. M. (2019). Triple artemisinin combination therapies: A new paradigm for the treatment of malaria? American Journal of Tropical Medicine and Hygiene, 101(5), 583. https://doi.org/10.4269/ajtmh.abstract2019
Moors, E. H. M. (2019). Responsible innovation and healthy ageing. In R. von Schomberg, & J. Hankins (Eds.), International Handbook on Responsible Innovation: A Global Resources (pp. 271-284). Edward Elgar Publishing. https://doi.org/10.4337/9781784718862
Ferreira, G. S., Veening-Griffioen, D. H., Boon, W. P. C., Moors, E. H. M., Gispen-de Wied, C. C., Schellekens, H., & van Meer, P. J. K. (2019). Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLoS One, 14(7), Article e0220325. https://doi.org/10.1371/journal.pone.0220325
Veening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Boon, W. P. C., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2019). Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. European Journal of Pharmacology, 859, 1-12. Article 172524. https://doi.org/10.1016/j.ejphar.2019.172524
S. Ferreira, G., Veening-Griffioen, D. H., Boon, W. P. C., Moors, E. H. M., Gispen-de Wied, C. C., Schellekens, H., & van Meer, P. J. K. (2019). A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLoS One, 14(6), Article e0218014. https://doi.org/10.1371/journal.pone.0218014

Popularising publications

Dekker, S. C., Driessen, P. P. J., van Egmond, N. D., Moors, E. H. M., Raven, R. P. J. M., Rietkerk, M. G., Worrell, E., van Dijk, J., Calisto Esquetini-Friant, P. M., Kraaijeveld, L. D., Mees, H. L. P., Vaas, J., Vermeulen, W. J. V., Vervoort, J. M., Verweij, P. A., Vijge, M. J., Wesseling, J. H., & Wojtynia, N. (2019). Klimaatakkoord: tijd voor politiek leiderschap! Dagblad Trouw.
https://dspace.library.uu.nl/bitstream/handle/1874/391527/klimaatbrief.pdf?sequence=1

2018

Scholarly publications

Arias Bustos, C., & Moors, E. H. M. (2018). Reducing post-harvest food losses through innovative collaboration: Insights from the Colombian and Mexican avocado supply chains. Journal of Cleaner Production, 199, 1020-1034. https://doi.org/10.1016/j.jclepro.2018.06.187
Grin, J., Hassink, J., Karadzic , V., & Moors, E. H. M. (2018). Transformative Leadership and Contextual Change. Sustainability, 10(7), Article 2159. https://doi.org/10.3390/su10072159
Van Oers, L. M., Boon, W. P. C., & Moors, E. H. M. (2018). The creation of legitimacy in grassroots organisations: A study of Dutch community supported agriculture. Environmental Innovation and Societal Transitions, 29, 55-67. https://doi.org/10.1016/j.eist.2018.04.002
Moors, E. H. M., Kukk Fischer, P., Boon, W. P. C., Schellen, F., & Negro, S. O. (2018). Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands. Technological Forecasting and Social Change, 128, 133-143. https://doi.org/10.1016/j.techfore.2017.11.011

Other output

Moors, E. H. M., Arentshorst, M. E., Boon, W. P. C., & Hoekman, J. (2018). Transition to distributed sustainable innovation models. Paper presented at 9th International Sustainability Transitions Conference (IST) 2018, Manchester, United Kingdom.
Boon, W. P. C., & Moors, E. H. M. (2018). Innovation policy for distributed innovation models in healthcare. Abstract 24-2. Abstract from EU-SPRI 2018, Paris, France.

2017

Scholarly publications

Moors, E. H. M., Hoekman, J., Kalkman, S., Arentshorst, M. E., Boon, W. P. C., & van Thiel, G. (2017). From mass to modular innovation. Towards distributed drug development models. Paper presented at International workshop on medical innovation (WOMI 2017), Reykjavik, Iceland.
Kooijman, M., Hekkert, M. P., van Meer, P. J. K., Moors, E. H. M., & Schellekens, H. (2017). How institutional logics hamper innovation: The case of animal testing. Technological Forecasting and Social Change, 118, 70-79. https://doi.org/10.1016/j.techfore.2017.02.003

Other output

Moors, E. H. M., & van Oers, L. M. (2017). Legitimacy creation in grassroots innovations: Community supported agriculture in the Netherlands. Paper presented at The 15th International Open and User Innovation Conference , Innsbruck, Austria.
Moors, E. H. M., & Grin, J. (2017). Transformative leadership and contextual change. Paper presented at 4th WINIR (World Interdisciplinary Network for Institutional Research) Conference:, Utrecht, Netherlands.
Grin, J., & Moors, E. H. M. (2017). Transformative leadership and contextual change. Paper presented at The 8th International Sustainability Transitions Conference, Gothenberg, Sweden.
Moors, E. H. M., & van Oers, L. (2017). Legitimacy creation in grassroots innovations. An empirical study into community supported agriculture in the Netherlands. Paper presented at The 8th International Sustainability Transitions Conference, Gothenberg, Sweden.
https://dspace.library.uu.nl/bitstream/handle/1874/351032/client_Id_KONGRESS_project_Id_17371.pdf?sequence=1
Boon, W. P. C., Hoekman, J., Moors, E. H. M., & Evers, G. W. (2017). Innovation for rare diseases – co-creation in innovation ecosystems in the Netherlands. Paper presented at Eu-SPRI Annual Conference 2017, Vienna, Austria.

2016

Scholarly publications

Boenink, M., van Lente, H., & Moors, E. (2016). Emerging Technologies for Diagnosing Alzheimer’s Disease: Innovating with Care. In M. Boenink, H. van Lente, & E. H. M. Moors (Eds.), Emerging Technologies for Diagnosing Alzheimer's Disease (pp. 1-17). (Emerging Technologies for Diagnosing Alzheimer's Disease). Palgrave Macmillan. https://doi.org/10.1057/978-1-137-54097-3_1
Weijman, J. M., Peine, A., Neven, L., & Moors, E. H. M. (2016). Technology nudges: How technology figures in practices of active and healthy ageing. Gerontechnology, 15(Supplement), 66S. https://doi.org/10.4017/gt.2016.15.s.726.00
Boenink, M., van Lente, H., & Moors, E. H. M. (2016). Emerging Technologies for Diagnosing Alzheimer’s Disease: Innovating with Care. In M. Boenink, H. van Lente, & E. Moors (Eds.), Emerging Technologies for Diagnosing Alzheimer's Disease : Innovating with Care (pp. 1-17). (Health, Technology and Society). Palgrave Macmillan UK. https://doi.org/10.1057/978-1-137-54097-3
Boenink, M., van Lente, H., & Moors, E. H. M. (2016). Diagnosing Alzheimer’s Disease: How to Innovate with Care. In M. Boenink, H. van Lente, & E. Moors (Eds.), Emerging Technologies for Diagnosing Alzheimer's Disease : Innovating with Care (pp. 263-275). (Health, Technology and Society). Palgrave Macmillan UK. https://doi.org/10.1057/978-1-137-54097-3
Moors, E. H. M., & Peine, A. (2016). Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment. In M. Boenink, H. van Lente, & E. Moors (Eds.), Emerging Technologies for Diagnosing Alzheimer's Disease : Innovating with Care (pp. 245-261). (Health, Technology and Society). Palgrave Macmillan UK. https://doi.org/10.1057/978-1-137-54097-3
Boenink, M., Van Lente, H., & Moors, E. H. M. (2016). Emerging Technologies for Diagnosing Alzheimer's Disease: Innovating with Care. (Health, Technology and Society). Palgrave Macmillan UK. https://doi.org/10.1057/978-1-137-54097-3
Kukk, P., Moors, E. H. M., & Hekkert, M. P. (2016). Institutional power play in innovation systems: The case of Herceptin®. Research Policy, 45(8), 1558-1569. https://doi.org/10.1016/j.respol.2016.01.016

Other output

Moors, E. H. M., Kukk, P., Boon, W. P. C., & Negro, S. O. (2016). Institutionalisation of markets for innovative health technologies: The case of personalised cancer medicine in the Netherlands. Abstract from 2016 Eu-SPRI Conference “Exploring New Avenues for Innovation and Research Policies, Lund, Sweden.

2015

Scholarly publications

Peine, A., Faulkner, A., Jæger, B., & Moors, E. (2015). Science, technology and the ‘grand challenge’ of ageing—Understanding the socio-material constitution of later life: Science, Technology and the “Grand Challenge” of Ageing. Technological Forecasting and Social Change, 93, 1-9. https://doi.org/10.1016/j.techfore.2014.11.010
Kukk, P., Moors, E. H. M., & Hekkert, M. P. (2015). The complexities in system building strategies — The case of personalized cancer medicines in England. Technological Forecasting and Social Change, 98(0), 47-59. https://doi.org/10.1016/j.techfore.2015.05.019
Peine, A., & Moors, E. H. M. (2015). Valuing health technology – habilitating and prosthetic strategies in personal health systems. Technological Forecasting and Social Change, 93, 68-81. https://doi.org/10.1016/j.techfore.2014.08.019
Schellekens, H., & Moors, E. (2015). Biosimilars or semi-similars? Nature Biotechnology, 33(1), 19-20. https://doi.org/10.1038/nbt.3083
van Meer, P., Ebbers, H. C., Kooijman, M., Wied, C. C. G., Silva-Lima, B., Moors, E. H. M., & Schellekens, H. (2015). Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discovery Today, 20(4), 483-490. https://doi.org/10.1016/j.drudis.2014.11.009

Other output

Moors, E. H. M. (2015). Verantwoorde Diagnostiek Innovatie: Verslag NWO Strategie bijeenkomst. Universiteit Utrecht.
Moors, E. H. M., & Peine, A. (2015). New value spaces for emerging health innovations. Abstract from EU-SPRI Conference 2015, Helsinki, Finland.

2014

Scholarly publications

Nahuis, R., & Moors, E. (2014). The inertia of a use regime. Why a celiac disease pill is conceived but not embraced? (ISU working paper series; Vol. 14, No. 03). Universiteit Utrecht. http://www.geo.uu.nl/isu/pdf/isu1403.pdf
Cuijpers, Y., van Lente, H., Boenink, M., & Moors, E. (2014). Quandries of Responsible Innovation: The Case of Alzheimer's Disease. In J. van den Hoven, N. Doorn, T. Swierstra, B.-J. Koops, & H. Romijn (Eds.), Responsible Innovation: Volume 1: Innovative Solutions for Global Issues (pp. 239-254). Springer. http://www.springer.com/gp/book/9789401789554
https://dspace.library.uu.nl/bitstream/handle/1874/308513/chp_3A10.1007_2F978_94_017_8956_1_13.pdf?sequence=1
Moors, E., & Lukkien, D. R. M. (2014). Healthcare innovations in an ageing society. In T. Michalek, L. Hebáková, L. Hennen, C. Scherz, L. Nierling, & J. Hahn (Eds.), Technology Assessement and Policy Areas of Great Transitions: Proceedings from the PACITA 2013 Conference in Prague (pp. 281-288). Parliaments and Civil Society in Technology Assessment (PACITA) project.. http://www.pacitaproject.eu/wp-content/uploads/2014/11/Conference-Book.pdf
https://dspace.library.uu.nl/bitstream/handle/1874/308516/Pages_281_288_from_Conference_Book.pdf?sequence=1
Boon, W. P. C., Moors, E. H. M., & Meijer, A. J. (2014). Exploring dynamics and strategies of niche protection. Research Policy, 43(4), 792-803. https://doi.org/10.1016/j.respol.2014.01.005
https://dspace.library.uu.nl/bitstream/handle/1874/303448/Boon.pdf?sequence=3
Moors, E. H. M., Cohen, A. F., & Schellekens, H. (2014). Towards a sustainable system of drug development. Drug Discovery Today, 19(11), 1711-1720. https://doi.org/10.1016/j.drudis.2014.03.004

Other output

Kukk, P., Moors, E. H. M., & Hekkert, M. P. (2014). The Impact of System Building on Personalized Cancer Therapeutics’ Innovation System - the case of Tarceva® in England. Abstract from 2014 Eu-SPRI Conference Science and Innovation Policy: Dynamics, Challenges, Responsibility and Practice, Manchester (UK), Manchester, United Kingdom.
Moors, E. H. M., Negro, S. O., Boon, W. P. C., Kukk, P., & Schellekens, H. (2014). Explaining the transition towards personalized health innovation systems. The case of personalized cancer treatment in the Netherlands. Abstract from 2014 Eu-SPRI Conference Science and Innovation Policy: Dynamics, Challenges, Responsibility and Practice, Manchester (UK), Manchester, United Kingdom.

2013

Scholarly publications

Ebbers, H. C., Mantel-Teeuwisse, A. K., Sayed-Tabatabaei, F. A., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. M. (2013). The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals. European Journal of Clinical Pharmacology, 69(2), 217-226. https://doi.org/10.1007/s00228-012-1317-3
Ebbers, H. C., Al-Temimi, E., Moors, E. H. M., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. M. (2013). Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules. BioDrugs, 27(2), 167-174. https://doi.org/10.1007/s40259-013-0012-y
Ebbers, H. C., van Meer, P. J. K., Moors, E. H. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Schellekens, H. (2013). Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discovery Today, 18(17-18), 872-879. https://doi.org/10.1016/j.drudis.2013.05.004
Meijer, A., Boon, W., & Moors, E. (2013). Stakeholder engagement in pharmaceutical regulation: Connecting technical expertise and lay knowledge in risk monitoring. Public Administration, 91(3), 696-711. https://doi.org/10.1111/padm.12027
Kooijman, M., van Meer, P. J. K., Gispen-de Wied, C. C., Moors, E. H. M., Hekkert, M. P., & Schellekens, H. (2013). The risk-based approach to ATMP development - Generally accepted by regulators but infrequently used by companies. Regulatory Toxicology and Pharmacology, 67(2), 221-225. https://doi.org/10.1016/j.yrtph.2013.07.014
van Meer, P. J. K., Kooijman, M., van der Laan, J. W., Moors, E. H. M., & Schellekens, H. (2013). The value of non-human primates in the development of monoclonal antibodies. Nature Biotechnology, 31(10), 882-3. https://doi.org/10.1038/nbt.2709
Janssen, M., & Moors, E. H. M. (2013). Caring for healthcare entrepreneurs - Towards successful entrepreneurial strategies for sustainable innovations in Dutch healthcare. Technological Forecasting and Social Change, 80(7), 1360-1374. https://doi.org/10.1016/j.techfore.2012.12.003
Cuijpers, Y. M., van Lente, H., Boenink, M., & Moors, E. H. M. (2013). Quandaries of Responsible Innovation: The Case of Alzheimer’s Disease. In J. van den Hoven, B.-J. Koops, H. Romijn, T. Swierstra, & N. Doorn (Eds.), Responsible Innovation1: Innovative Solutions for Global Issues (pp. 239–254). Springer. https://doi.org/10.1007/978-94-017-8956-1_13
https://dspace.library.uu.nl/bitstream/handle/1874/385395/Cuijpers2014_Chapter_QuandariesOfResponsibleInnovat.pdf?sequence=1
van Meer, P. J. K., Kooijman, M., Brinks, V., Gispen-de Wied, C. C., Silva-Lima, B., Moors, E. H. M., & Schellekens, H. (2013). Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. mAbs, 5(5), 810-816. https://doi.org/10.4161/mabs.25234

Professional publications

Moors, E. H. M. (2013). Durf je nek uit te steken. Pandora, Tijdschrift van het Vrouwennetwerk UU, Juli 2013, 7. http://www.fss.uu.nl/vn/pdf_bestanden/pandora-2013-2.pdf
https://dspace.library.uu.nl/bitstream/handle/1874/385345/pandora_2013_juli.pdf?sequence=1

Other output

Moors, E. H. M. (2013). Sustainability transitions in agriculture: the case of Dutch dairy farming. Abstract from 4th International Conference on Sustainability Transitions, Zurich, Switzerland.
Moors, E. H. M. (2013). Duurzaam Innoveren, de kunst van het verbinden. Utrecht University.
Moors, E. H. M. (2013). Healthcare innovations in an ageing society. Abstract from The European Technology Assessment Conference: Technology Assessment and Policy Areas of Great Transitions, Prague, Czech Republic.
Kukk, P., Moors, E. H. M., & Hekkert, M. P. (2013). Speeding up the Development and Implementation of Personalized Cancer Therapeutics – the case of Herceptin© in England. Abstract from 2013 EU-Spri Forum Conference, Madrid, Spain. http://www.euspri-madrid2013.org/pdf/1160.pdf
Moors, E. H. M. (2013, Nov 8). Jurylid.

2012

Scholarly publications

Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Sayed Tabatabaei, F. A., Schellekens, H., & Leufkens, H. G. M. (2012). A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals. Drug Safety, 35(5), 417-427. https://doi.org/10.2165/11597850-000000000-00000
Van Meer, P., Kooijman, M., van der Laan, J. W., Moors, E., & Schellekens, H. (2012). The future of non-human primates in the development of biopharmaceuticals. ATLA : Alternatives to Laboratory Animals, 40(4), 32.
https://dspace.library.uu.nl/bitstream/handle/1874/385550/Pagina_s_van_The_Future_of_Non_Human_Primates.pdf?sequence=1
Kooijman, M., Van Der Zwan, D., Van Meer, P., Moors, E., Schellekens, H., & Hekkert, M. (2012). Understanding the lengthy process to replace the draize test. ATLA : Alternatives to Laboratory Animals, 40(4), A15-A16.
https://dspace.library.uu.nl/bitstream/handle/1874/385314/UnderstandingAbstract.pdf?sequence=1
van Meer, P. J. K., Kooijman, M., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2012). The ability of animal studies to detect serious post marketing adverse events is limited. Regulatory Toxicology and Pharmacology, 64(3), 345-349. https://doi.org/10.1016/j.yrtph.2012.09.002
Zwartkruis, J. V., Moors, E. H. M., Farla, J. C. M., & van Lente, H. (2012). Agri-food in search of sustainability: cognitive, interactional and material framing. Journal on Chain and Network Science, 12(2), 99-110. https://doi.org/10.3920/JCNS2012.x006
Kooijman, M., van Meer, P. J. K., Moors, E. H. M., & Schellekens, H. (2012). Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance? Expert Opinion on Drug Safety, 11(5), 797-801. https://doi.org/10.1517/14740338.2012.712110
Schellekens, H., & Moors, E. H. M. (2012). Reply to In support of the European Union biosimilar framework. Nature Biotechnology, 30(8), 748-749. https://doi.org/10.1038/nbt.2327
Moors, E. H. M. (2012). Functional foods: regulation and innovations in the EU. Innovation, 25(4), 424-440. https://doi.org/10.1080/13511610.2012.726407
Nahuis, R., Moors, E. H. M., & Smits, R. E. H. M. (2012). User producer interaction in context. Technological Forecasting and Social Change, 79(6), 1121-1134. https://doi.org/10.1016/j.techfore.2012.01.005
Herrmann, A. M., Taks, J. L., & Moors, E. H. M. (2012). Beyond regional clusters: On the importance of geographical proximity for R&D collaborations in a global economy - the case of the flemish biotech sector. Industry and Innovation, 19(6), 499-516. https://doi.org/10.1080/13662716.2012.718876

Other output

Ebbers, H. C., Al-Temimi, E., Moors, E. H., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. (2012). A comparison of post-authorization adverse events of biopharmaceuticals and small molecules within the same anatomical therapeutic chemical class. Pharmacoepidemiology and Drug Safety, 21(S3), 43. Article 85. https://doi.org/10.1002/pds.3324
Cuijpers, Y. M., Moors, E. H. M., Laan, A. L., & van Lente, H. (2012). Futures of Alzheimer's Disease and early diagnostics: comparing two anticipatory practices. Abstract from The 4s/EASST conference, Copenhagen, Denmark.
Quist, J., van Lente, H., Moors, E. H. M., & van der Poel, I. (2012). Responsible and Sustainable Innovation. Paper presented at Convenors of Open Panel Session at 4S/EASST Joint Meeting, Copenhagen, Denmark.
Moors, E. H. M. (2012). Maatschappelijk Onderzoek Life Sciences. Paper presented at Invited discussant at Centre for Society & Life Sciences CSG/NGI Netwerk bijeenkomst, Utrecht, The Netherlands.
Moors, E. H. M., Boon, W. P. C., & Meijer, A. J. (2012). Managing urgent innovations. Exploring restrictive and broad strategic nich management. Abstract from 2012 Eu-SPRI Conference, Karlruhe, Baden-Württemberg, Germany.
Kooijman, M., van de Meer, P., Moors, E. H. M., Schellekens, H., & Hekkert, M. P. (2012). Transition towards replacing animal tests in safety assessment of cosmetics and chemicals: a combined TIS-MLP framework. Abstract from 2012 Eu-SPRI Conference, Karlruhe, Baden-Württemberg, Germany.
Cuijpers, Y. M., van Lente, H., & Moors, E. H. M. (2012). Assessing the implications of early diagnostics for Alzheimer's Disease. Abstract from International conference, Towards personalized medicine? Exploring biomarkers in practice, Vienna, Austria.
Kooijman, M., van de Meer, P., Moors, E. H. M., Schellekens, H., & Hekkert, M. P. (2012). Understanding transition dynamics using a combined TIS-MLP approach. Abstract from IST 2012 - International Conference on Sustainability Transitions, Lyngby, Denmark. http://www.ist2012.dk/index.php/IST/IST2012/paper/viewPaper/198
Ebbers, H. C., Al-Temimi, E., Moors, E. H. M., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. (2012). A comparison of post-authorization adverse events of biopharmaceuticals and small molecules. Abstract from WHO Winter Meeting 2012, Utrecht, The Netherlands.
Moors, E. H. M., & Nahuis, R. (2012). Technological versus use regimes. Abstract from EASST 2012 : Biennial Conference of the European Association for the Study of Science and Technology (EASST) 2012, Copenhagen, Denmark.
Moors, E. H. M. (2012). Towards a sustainable system of drug development. Abstract from 2013 EU-Spri Forum Conference, Madrid, Spain.
Moors, E. H. M., & Pennings, J. (2012). Coparing the European and US nutraceuticals innovation system. Abstract from IST 2012 - 3rd International Conference on Sustainability Transitions, Copenhagen, Denmark.
van Lente, H., Quist, J., & Moors, E. H. M. (2012). Comparing Resonsible and Sustainable Innovation. Paper presented at Organization special sessions at 4S/EASST Conference, Copenhagen, Denmark.

2011

Scholarly publications

Taks, J. L., Herrmann, A. M., & Moors, E. H. M. (2011). Does regional proximity still matter in a global economy? The case of flemish biotech ventures. Frontiers of Entrepreneurship Research, 31(16), 516-529. Article 1. https://doi.org/10.1080/13662716.2012.718876
https://dspace.library.uu.nl/bitstream/handle/1874/396530/Does_Regional_Proximity_Still_Matter_in_Global_Economy_.pdf?sequence=1
Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. (2011). Today's challenges in pharmacovigilance: what can we learn from epoetins? Drug Safety, 34(4), 273-287. https://doi.org/10.2165/11586350-000000000-00000
Ebbers, H. C., Mante Teeuwisse, A. K., Sayed Tabatabaei, F. A., Moors, E. H., Schellekens, H., & Leufkens, H. G. (2011). The outcome of psur assessments of biopharmaceuticals. Drug Safety, 34(10), 888.
https://dspace.library.uu.nl/bitstream/handle/1874/385551/Pagina_s_van_2011_Article_InternationalSocietyOfPharmaco.pdf?sequence=1
Boon, W. P. C., Moors, E. H. M., Kuhlmann, S., & Smits, R. E. H. M. (2011). Demand articulation in emerging technologies: intermediary user organizations as co-producers? Research Policy, 40(2), 242-252. https://doi.org/10.1016/j.respol.2010.09.006
Boenink, M., Cuijpers, Y. M., Laan, A. L., van Lente, H., & Moors, E. H. M. (2011). Assessing the Sociocultural Impacts of Emerging Molecular Technologies for the Early Diagnosis of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011(ID 184298). https://doi.org/10.4061/2011/184298
Brabers, A. E. M., Moors, E. H. M., van Weely, S., & de Vrueh, R. L. (2011). Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe. Orphanet Journal of Rare Diseases, 6(59). https://doi.org/10.1186/1750-1172-6-59
Schellekens, H., Moors, E. H. M., & Leufkens, H. G. M. (2011). Drug Regulatory Systems Must Foster Innovation. Science, 332(6026), 174-175. https://doi.org/10.1126/science.332.6026.174
Moors, E. H. M., Boon, W. P. C., Nahuis, R., & Vandeberg, R. L. J. (2011). User-Producer Interactions in Emerging Pharmaceutical and Food Innovations. In F. Flowers, & F. Henwood (Eds.), Perspectives on User Innovation (pp. 161-188). (Series on Technology Management; No. Vol. 16, Chapter 7). Imperial College Press. https://doi.org/10.1142/9781848167001_0007
Moors, E. H. M. (2011). Demanding users and genomics decisions. In D. J. Boerwinkel, & A. J. Waarlo (Eds.), Genomics Education for Decision-making (pp. 43-48). Freudenthal Institute for Sicence and Mathematics Education, Utrecht University.

Other output

Van Meer, P. J. K., Kooijman, M., Moors, E. H. M., & Schellekens, H. (2011). The value of non-human primates in the development of therapeutic monoclonal antibodies. ALTEX-Alternatives to Animal Experimentation, 28(Special issue), 52.
https://dspace.library.uu.nl/bitstream/handle/1874/314495/WC8_Abstracts.pdf?sequence=1
Kooijman, M., Van Meer, P. J. K., Moors, E. H. M., Hekkert, M. P., & Schellekens, H. (2011). Implementation of in vitro replacement technologies in regulatory drug testing - An innovation systems perspective. ALTEX-Alternatives to Animal Experimentation, 28(Special issue), 188.
https://dspace.library.uu.nl/bitstream/handle/1874/314494/WC8_2.pdf?sequence=1
Taks, J. L., Herrmann, A. M., & Moors, E. H. M. (2011). Does regional proximity still matter in a global economy? The case of flemish biotech ventures. Abstract from Babson College Entrepreneurship Research Conference. http://digitalknowledge.babson.edu/fer/vol31/iss16/1

2010

Scholarly publications

Ebbers, H. C., Mantel-Teeuwisse, A. K., Sayed Tabatabaei, F. A., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. M. (2010). The contribution of periodic safety reports (PSURs) to safety related regulatory actions of biopharmaceuticals. Drug Safety, 33(10), 919. https://doi.org/10.2165/11532470-000000000-00000
Boon, W., Moors, E., & Leufkens, H. (2010). Patient advocacy and articulation of expectations about pharmaceutical innovations. (Innovation Studies Utrecht (ISU) Working Paper Series). http://www.geo.uu.nl/isu/pdf/isu1001.pdf
Boon, W. P. C., Moors, E. H. M., Meijer, A., & Schellekens, H. (2010). Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clinical Pharmacology and Therapeutics, 88(6), 848-853. https://doi.org/10.1038/clpt.2010.207
Boon, W. P. C., Moors, E. H. M., & Meijer, A. (2010). Governing ex-post drug risk surveillance: linking different epistemic cultures. In EASST 010 - Practicing science and technology, performing the social
https://dspace.library.uu.nl/bitstream/handle/1874/385571/Pagina_s_van_Governing_ex_post_drug_risk_surveillance.pdf?sequence=1
Zwartkruis, J. V., Klerkx, L., Moors, E. H. M., Farla, J. C. M., & Smits, R. E. H. M. (2010). Co-innovation in sustainable laying hen husbandry systems: Investigating the interactive framing of sustainability. In I. Darnhofer, & M. Groetzer (Eds.), Building sustainable rural futures: The added value of systems approaches in times of change and uncertainty (pp. 413-422).
Peine, A., & Moors, E. H. M. (2010). Images of aging: How science and technology studies and gerontechnology might benefit each other. Gerontechnology, 9(2), 241-242. https://doi.org/10.4017/gt.2010.09.02.222.00
https://dspace.library.uu.nl/bitstream/handle/1874/385525/Images_of_aging.pdf?sequence=1
Schellekens, H., & Moors, E. H. M. (2010). Clinical comparability and European biosimilar regulations. Nature Biotechnology, 28(1), 28-31. https://doi.org/10.1038/nbt0110-28
van der Valk, T., Meeus, M. T. H., Moors, E. H. M., & Faber, J. (2010). R&D collaboration in the life sciences: Finding partners and the role of resource-based inducements and opportunities. International Journal of Innovation Management, 14(2), 179-199. https://doi.org/10.1142/S136391961000260X

Other output

Moors, E. H. M., Meijer, A. J., & Boon, W. P. C. (2010, Jul 7). Organizer 2nd Valorisation workshop NWO - Responsible Innovation project on New Modes of Governing Pharmacovigilance.
Moors, E. H. M. (2010). Member Peer Review Committee of the ELSAGEN-Initiative Ethical, Legal, Socio-cultural and economic aspects of Genomics and related sciences.
Moors, E. H. M. (2010). Member NWO-ZonMW Programme Committee Innovation Programme Revalidation.
Moors, E. H. M. (2010, Mar 1). Jury Open Technology Programme (OTP) Technologiestichting STW.
Boon, W. P. C., Moors, E. H. M., & Meijer, A. J. (2010). Ex-postdrug risk surveillance: Linking different epistemic cultures. Paper. Paper presented at Annual Conference of the European Association for the Study of Science and technology, Trento.
Moors, E. H. M. (2010, May 3). Member Peer Review Committee German ELSA Programme.
Moors, E. H. M., Meijer, A. J., & Boon, W. P. C. (2010, Jan 21). Organizer 1st Valorisation workshop NWO - Responsible Innovation project on New Modes of Governing Pharmacovigilance.

2009

Scholarly publications

van der Valk, T., Moors, E. H. M., & Meeus, M. T. H. (2009). Conceptualizing patterns in the dynamics of emerging technologies: The case of biotechnology developments in the Netherlands. Technovation, 29(4), 247-264. https://doi.org/10.1016/j.technovation.2008.09.005
Propp, T., & Moors, E. H. M. (2009). Will genomics erode public health and prevention? A scenario of unintended consequences in the Netherlands. Science and Public Policy, 36(3), 199-213. https://doi.org/10.3152/030234209X430884
Propp, T., & Moors, E. H. M. (2009). The impact of genomics on colorectal cancer research, innovation and future healthcare in the Netherlands: Expectations dynamics, forecasting tools, scenarios and recommendations, End-report of the CSG-I project. Genomics based convergence of food and health: changing governance arrangements (2006-2008). Unknown Publisher.

Other output

Boenink, M., van Lente, H., & Moors, E. H. M. (2009). Responsible early diagnostics for Alzheimer's Disease. Poster session presented at Poster presentation N.W.O.-MWI Meeting at Nemo, Amsterdam, The Netherlands.
Moors, E. H. M. (2009, Jun 26). Invited External Examiner for the Examination in Technology Policy for the degree of Master of Philosophy.
Moors, E. H. M., Boon, W. P. C., & Meijer, A. (2009). New Modes of Governing Pharmacovigilance. Poster session presented at Poster presentation N.W.O.-MVI Meeting at Nemo, Amsterdam, The Netherlands.
Moors, E. H. M. (2009). Member NWO-ZonMW Programmacommissie innovatieprogramma Revalidatie.
Moors, E. H. M. (2009, Aug 14). Member Peer Review Committee of the ELSAGEN-Initiative (Ethical, Legal, Socio-cultural and economic aspects of Genomics and related sciences).
Moors, E. H. M., & Nahuis, R. (2009, Jun 17). User producer interaction in context. From integration to configuration in therapeutic antibody development. http://www2.druid.dk/conferences/viewpaper.php?id=5896&cf=32
Moors, E. H. M. (2009). Societal implications of converging technologies. An assessment approach from an innovation studies perspective. Paper presented at Invited panel member SPT (Society for Philosopy and Technology). Conference 2009 on Converging Technologies, Changing Societies at Twente University, Enschede, The Netherlands.
Moors, E. H. M. (2009, Apr 1). Invited discussant at Expertmeeting on: "Maatschappelijke betekenis van biotechnologische trends", in het kader van Trendanalyse Biotechnologie 2009.

2008

Scholarly publications

Boon, W. P. C., Moors, E. H. M., Kuhlmann, S., & Smits, R. E. H. M. (2008). Demand articulation in intermediary organisations: The case of orphan drugs in the Netherlands. Technological Forecasting and Social Change, 75(5), 644-671. https://doi.org/10.1016/j.techfore.2007.03.001
Moors, E. H. M., Boon, W. P. C., Nahuis, R., & Vandeberg, R. (2008). User-producer interactions in emerging pharmaceutical and food innovations. International Journal of Innovation Management, 12(3), 459-487.
https://dspace.library.uu.nl/bitstream/handle/1874/387855/user_producer.pdf?sequence=1
Boon, W., & Moors, E. (2008). Exploring emerging technologies using metaphors - A study of orphan drugs and pharmacogenomics. Social Science & Medicine, 66(9), 1915-1927. https://doi.org/10.1016/j.socscimed.2008.01.012

Professional publications

Moors, E. H. M. (2008). Challenges for the adoption of future biosimilars. In H. Schellekens, & A. G. Vulto (Eds.), Biopharmaceuticals EJHP Practice PPME.
https://dspace.library.uu.nl/bitstream/handle/1874/385570/EJHPMoors2007.pdf?sequence=1
Moors, E. H. M., & Schellekens, H. (2008). Medical Biotechnology and sustainable drug development. In H. Schellekens, & A. G. Vulto (Eds.), Biopharmaceuticals EJHP Practice PPME.

Other output

Moors, E. H. M. (2008). Guiding Life Sciences Governance in the Age of Genomics. Paper presented at Chair and organizer of conference session for the International Conference-Genomics an Society: Setting the Agenda, Amsterdam, The Netherlands.
Vandeberg, L. L. J., & Moors, E. H. M. (2008). Conference session on 'Interaction and Boundary Crossing in Nutrigenomics. Paper presented at Chair and organisation of conference session for the International Conference - Genomics and Society: Setting the Agenda, Amsterdam, The Netherlands.
Moors, E. H. M. (2008). Different kinds of translation: How genomics challenges health care. Paper presented at Chair + organizer of Conference session at 4S/EASST Conference, Rotterdam, The Netherlands.
Moors, E. H. M. (2008). Dynamics of genomics innovations and the role of users. Paper presented at Chair and organizer of conference session for the International Conference - Genomics and Society: Setting the Agenda, Amsterdam, The Netherlands.

2007

Scholarly publications

Vandeberg, R., Moors, E. H. M., & Kuhlmann, S. (2007). Multi-stakeholder interaction in emerging nutrigenomics - an interactive learning approach. In Cesagen 2007. London
Moors, E. H. M., & Faber, J. (2007). Orphan drugs: Unmet societal need for non-profitable privately supplied new products. Research Policy, 36, 336-354. https://doi.org/10.1016/j.respol.2006.12.006
Achterbergh, R., Lakeman, P., Stemerding, D., Moors, E. H. M., & Cornel, M. C. (2007). Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: A sociotechnical analysis. Health Policy, 83, 277-286. https://doi.org/10.1016/j.healthpol.2007.02.007
Moors, E. H. M. (2007). Challenges for the adoption of future biosimilars. EJHP Practice, 13(5), 57-58.
https://dspace.library.uu.nl/bitstream/handle/1874/385536/EJHPMoors2007.pdf?sequence=1
Propp, T., & Moors, E. H. M. (2007). Tools for assessing inter-sector convergences on genomics based personalized health. In Conference Proceedings Centre of Society and Genomics Research Day

2006

Scholarly publications

Moors, E. H. M. (2006). Technology strategies for sustainable metals production systems: A case study of primary aluminium production in The Netherlands and Norway. Journal of Cleaner Production, 14, 1121-1138. https://doi.org/10.1016/j.jclepro.2004.08.005
Moors, E. H. M., & Dijkema, G. P. J. (2006). Embedded industrial production systems: Lessons from waste management in zinc production. Technological Forecasting and Social Change, 73, 250-265. https://doi.org/10.1016/j.techfore.2004.03.006

Professional publications

Moors, E. H. M. (2006). Technology choices in Zinc production. CML and staff Industrial Ecology, Course introduction Industrial Ecology and Symbiosis. In Course Introduction Industrial Ecology and Symbiosis (pp. 183-240). (TUD/UL/EUR). TUD/UL.EUR, CML and Staff Industrial Ecology.

2005

Scholarly publications

Moors, E. H. M., Mulder, K. F., & Vergragt, P. J. (2005). Towards cleaner production: barriers and strategies in the base metals producing industry. Journal of Cleaner Production, 13, 657-668. https://doi.org/10.1016/j.jclepro.2003.12.010

2004

Scholarly publications

Moors, E. H. M., Rip, A., & Wiskerke, J. S. C. (2004). The dynamics of innovation: A multilevel co-evolutionary perspective. In J. S. C. Wiskerke, & J. D. van der Ploeg (Eds.), Seeds of Transistion, Essays on novelty production, niches and regimes in agriculture (pp. 31-56). Koninklijke Van Gorcum.
https://dspace.library.uu.nl/bitstream/handle/1874/385568/Dynamics_of_Innovation.pdf?sequence=1

2003

Scholarly publications

Meeus, M. T. H., Suurs, R. A. A., Faber, J., Moors, E. H. M., & Hekkert, M. P. (2003). Concurrentievermogen, Innovatie en Samenwerking in de provincie Utrecht. Een empirisch onderzoek naar innovatief gedrag met 80 benchmark studies voor individuele ondernemeningen. UU GEOG Copernicus.
Moors, E. H. M., van der Giessen, A., Enzing, C., & Smits, R. E. H. M. (2003). User-producer interaction in functional genomics innovations. Conference 'Knowledge and Economic and Social Change: New Challenges to Innovation Studies. ASEAT.
Moors, E. H. M., Enzing, C., van der Giessen, A., & Smits, R. E. H. M. (2003). User-producer interactions in functional genomics innovations. Innovation: Management, Policy & Practice, 5(2/3), 120-143.
Kemp, R., & Moors, E. H. M. (2003). Modulating dynamics in transport for climate protection. In M. Faure, J. Gupta, & A. Nentjes (Eds.), Climate change and the Kyoto Protocol. The role of Institutions and Instruments to Control Global Change. (pp. 312-339). Edward Elgar Publishing.

Other output

Moors, E. H. M., Kleijwegt, T., & Otten, A. (2003). Regulating biotech innovations. Case studies from tissue engineering and SNA-vaccines. Paper presented at Presentation at Biotech Society Conference, Espoo, Finland.

2002

Scholarly publications

Moors, E. H. M., Enzing, C., van der Giessen, A., & Smits, R. E. H. M. (2002). User-producer interaction in functional genomics innovations. Copernicus Institute for Susyainable Development and Innovation.
Moors, E. H. M., & Vergragt, P. J. (2002). Technology choices for sustainable industrial production. International Journal of Innovation Management, 6(3), 277-299.
Moors, E. H. M., & Mulder, K. F. (2002). Industry in sustainable development. The contribution of regime changes to radical technical innovation in industry. International Journal of Technology, Policy and Management, 2(4), 434-454.
Hekkert, M. P., Meeus, M. T. H., Faber, J., & Moors, E. H. M. (2002). Exploratory analysis of the transition towards fuel cell technology in the transportation sector: trajectories and actor perspectives. In Greening of Industry Conference

Other output

Moors, E. H. M., Faber, J., Hekkert, M. P., & Meeus, M. T. H. (2002). Innovation systems barriers of orphan drugs developments in the Netherlands. Paper presented at Paper presented at Greening of Industry Network Conference, Goteborg, Sweden.

2001

Scholarly publications

Moors, E. H. M., Wiskerke, H., & Rip, A. (2001). The dynamics of innovation: a sociotechnical perspective. (Workbook ed.) NWO project AGRINOVIM, CSSTS.
Moors, E. H. M., & Geels, F. W. (2001). Dynamics of sociotechnical change in transport & mobility: Opportunities for governance. (Global Air Pollution and Climate Change, report no. 410 200 071 ed.) Dutch National Research Programme.
Moors, E. H. M. (2001). The critical role of networks in embedded industrial production systems. Lessons from waste management in zinc production. 5th Int. Conference on Technology, Policy and Innovation.